Seed Therapeutics
  • Mission
  • Drug Discovery
  • Leadership
  • Pipeline
  • Communications
  • Careers
Select Page

Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer

by Andrey Alimetov | Oct 14, 2020 | Press Releases

info@seedtherapeutics.com  info@seedtherapeutics.com   PRESS RELEASES Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer “Molecular Glue” Protein Degradation Serves as Alternative Approach...
Next Entries »

Recent Posts

  • SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
  • SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
  • SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
  • Nature: Protein degraders push into novel target space
  • SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors

Recent Comments

    Seed Therapeutics logo
    • LinkedIn
    • Twitter

    ©2023 All rights reserved – SEED Therapeutics, Inc.         Privacy Policy | Terms of Use | Accessibility Statement

    411 Swedeland Road, Suite 1000 King of Prussia, PA 19406, United States           info@seedtherapeutics.com

    We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy Policy